Amendment Nine HHS-NIH-NIAID-BAA2020-1.pdf
PDF 208 KB Posted
- Attached to
- 2020 NIAID Omnibus Broad Agency Announcement
- Solicitation number
- HHS-NIH-NIAID-BAA2020-1
About this file
This document is an amendment to a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases seeking proposals for various research areas. The announcement includes five research areas related to vaccine development, therapeutics, diagnostics and medical countermeasures. Proposals are due on April 9, 2020 for research areas 001, 003, 004 and 005, which involve radiation countermeasures, vaccine candidates for biodefense and emerging diseases, therapeutics for biodefense and antimicrobial resistant infections, and diagnostics for biothreats. Research area 002 involves vaccine development for acute flaccid myelitis and has a proposal due date of February 28, 2020. The agency estimates costs of up to $2 million, $3 million, and $11.5 million for various research areas and number of awards. The performance periods for contracts are not to exceed three to five years depending on the research area.
View the file
Other files
Show all 12
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
HHS-NIH-NIAID-BAA2020-1 Page 1 of 3 Amendment Nine (9)
NIAID 2020 OMNIBUS BROAD AGENCY ANNOUNCEMENT
HHS-NIH-NIAID-BAA2020-1
AMENDMENT NINE (9)
OFFICE OF ACQUISITIONS
National Institute of Allergy and Infectious Diseases (NIAID)
5601 Fishers Lane, Room 3D38, MSC 9821
Bethesda, MD 20892-9821
Solicitation Number: HHS-NIH-NIAID-BAA2020-1
Date of Solicitation Issuance: January 3, 2020
Date of Amendment
Nine (9) Issuance: March 20, 2020
Number of Pages: 3
Proposal Due Dates:
The hour and date specified for receipt of offers for each Research Area remains unchanged:
RESEARCH
AREA
NIAID
DIVISION
TITLE RECEIPT DATE AND
TIME
001 DAIT Development of Radiation/Nuclear Medical Countermeasures (MCMs)
3:00 PM Eastern Time, 04/09/2020
003 DMID Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
3:00 PM Eastern Time, 04/09/2020
004 DMID Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
3:00 PM Eastern Time, 04/09/2020
005 DMID Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases
3:00 PM Eastern Time, 04/09/2020
Points of Contact:
Division of Allergy, Immunology, and Transplantation (DAIT)
Research Area 001: Development of Radiation/Nuclear Medical Countermeasures (MCMs)
Liem Nguyen, Contracting Officer
Email: liem.nguyen@nih.gov
Phone: 240-669-5144
Division of Microbiology and Infectious Diseases (DMID) mailto:liem.nguyen@nih.gov
HHS-NIH-NIAID-BAA2020-1 Page 2 of 3
Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging
Infectious Diseases
Research Area 004: Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant
(AMR) Infections and Emerging Infectious Diseases
Research Area 005: Advanced Development of Diagnostics for Biothreats and Emerging Infectious
Diseases
Primary Contact:
Swee L. Teo, Contracting Officer
Email: teosl@niaid.nih.gov
Phone: 240-669-5173
Secondary Contact:
Brian Madgey, Contracting Officer
Email: brian.madgey@nih.gov
Phone: 240-627-3712
Offerors MUST acknowledge receipt of the amendment by Amendment number (s) and date of the amendment. Failure to receive your acknowledgment of this amendment may result in the rejection of your proposal.
Except as provided herein, all terms and conditions of the solicitation remain unchanged and in full force and effect.
PURPOSE OF SOLICITATION AMENDMENT
The purpose of Amendment Nine is to:
I) Provide responses to questions received regarding the solicitation.
The responses are offered for information only and do not modify or become part of this solicitation.
Additional amendments may be provided as needed to address further questions and their related responses. All potential offerors are advised to refer back to all previous amendments for additional questions and clarification.
I. The Government’s responses to questions received regarding this solicitation are as follows:
GENERAL QUESTIONS
Question 1: We intend to respond to the OMNIBUS solicitation for infection vaccines but are not familiar with the eCPS process.
1. Does the PI need to register a new account similar to an ECommons or Grants.Gov account?
2. Does the PI submit directly to the portal?
3. Can a PI designee submit on their behalf?
4. Does an institutional official need to register the institution in eCPS? -or-mailto:teosl@niaid.nih.gov mailto:brian.madgey@nih.gov
HHS-NIH-NIAID-BAA2020-1 Page 3 of 3
5. Does the submission need to come from an authorized official for the organization in which case, we will apply the responses from #1 and #4.
Response: Either the Principal Investigator, designee, or an institutional official can submit the proposal in eCPS. See Section 4.3.2.1.2 – Online Submission of Electronic Proposals (page 61).
PLEASE NOTE: In the questions/responses above, specific organizational names have been removed or replaced where possible as well as other minor adjustments.
File details come from the government source that posted it. Updated .